Professor Lu Shichun: Hepatobiliary Cancer and Liver Transplant Specialist
Professor Lu Shichun is a senior hepatobiliary and pancreatic surgeon, professor, doctoral supervisor, and academic leader at the Chinese PLA General Hospital in Beijing. His clinical work focuses on liver and biliary tumors, complex hepatobiliary surgery, multidisciplinary liver-cancer treatment, end-stage liver disease, and liver transplantation.
International patients can learn more about the hospital and specialist services in our Chinese PLA General Hospital international patient guide.
Clinical and Academic Focus
- hepatocellular carcinoma;
- intrahepatic and extrahepatic cholangiocarcinoma;
- gallbladder and complex biliary tumors;
- pancreatic and periampullary tumors;
- major and repeat liver resection;
- liver transplantation;
- immunotherapy and targeted treatment around surgery;
- liver fibrosis and end-stage liver disease; and
- second opinions for complex or recurrent hepatobiliary cancer.
Hepatocellular Carcinoma
Hepatocellular carcinoma is the most common primary liver cancer and often develops in the setting of hepatitis B or C, cirrhosis, alcohol-related liver disease, or metabolic liver disease.
Treatment depends on tumor number and size, vascular invasion, spread outside the liver, liver function, portal hypertension, performance status, and previous therapy. Options may include resection, transplantation, ablation, embolization, radiation, targeted medicine, immunotherapy, or a combination.
Liver Resection
Liver resection can provide long-term disease control for selected patients when the tumor can be removed while leaving enough functioning liver. Planning may use volumetric imaging, liver-function testing, vascular reconstruction, portal-vein embolization, or staged surgery.
Major surgery is not suitable for every patient with technically removable disease. Cirrhosis, portal hypertension, future liver remnant, tumor biology, and alternatives must be considered.
Liver Transplantation
Liver transplantation replaces a failing or cancer-bearing liver with a donor organ. It may be considered for selected patients with end-stage liver disease, acute liver failure, or liver cancer that meets accepted transplant criteria.
Professor Lu has participated in more than one thousand liver-transplant procedures. Eligibility still depends on detailed medical assessment, tumor stage, infection status, cardiopulmonary fitness, psychosocial review, donor-organ policy, and current hospital approval.
Bridging and Downstaging Treatment
Patients awaiting transplantation may receive ablation, transarterial therapy, radiation, or systemic medicine to control disease. Downstaging aims to reduce selected tumors to within transplant criteria.
Response must be assessed by both imaging and tumor biology. Successful shrinkage does not automatically guarantee transplant eligibility.
Immunotherapy and Targeted Treatment
Immune-checkpoint inhibitors and targeted medicines have expanded treatment options for advanced liver cancer. In selected patients, they may also be used before or after surgery as part of a multidisciplinary plan.
Timing around transplantation requires particular caution because immunotherapy can increase the risk of rejection. Treatment should be coordinated by experienced liver-cancer and transplant teams.
Cholangiocarcinoma and Biliary Tumors
Bile-duct cancers vary by location and can involve major vessels, the liver, pancreas, and regional lymph nodes. Evaluation may require contrast-enhanced CT, MRI with MRCP, endoscopy, biopsy, and molecular profiling.
Complex surgery can include major liver resection, bile-duct reconstruction, vascular procedures, or pancreatic surgery. Treatment should be planned in a multidisciplinary setting.
Liver Fibrosis and End-Stage Liver Disease
Progressive fibrosis can lead to cirrhosis, portal hypertension, ascites, bleeding, encephalopathy, infection, kidney dysfunction, and liver cancer. Professor Lu’s research has also examined molecular mechanisms driving liver fibrosis.
Management includes treatment of the underlying liver disease, prevention of complications, nutrition, cancer surveillance, and timely transplant evaluation.
Who May Consider a Consultation?
- patients with newly diagnosed or recurrent liver cancer;
- patients considering major or repeat liver resection;
- patients with tumors involving major liver vessels;
- patients with cholangiocarcinoma or gallbladder cancer;
- patients evaluating immunotherapy before or after surgery;
- patients with cirrhosis or end-stage liver disease considering transplantation;
- patients seeking review of transplant, bridging, or downstaging options; or
- patients with conflicting recommendations about complex hepatobiliary surgery.
Medical Records to Prepare
- a concise diagnosis and treatment timeline;
- contrast-enhanced liver CT and MRI in original DICOM format;
- MRCP, PET-CT, angiography, and chest imaging when available;
- pathology reports, glass slides, paraffin blocks, and molecular results;
- all surgery, ablation, embolization, radiation, and systemic-treatment records;
- AFP, PIVKA-II, CA19-9, CEA, viral-hepatitis, liver, kidney, and coagulation results;
- portal-hypertension and endoscopy records;
- transplant evaluations and donor information when applicable;
- a complete medication list; and
- a clear list of treatment goals and questions.
Planning an International Consultation
Vomiting blood, black stool, confusion, severe jaundice, rapidly increasing abdominal swelling, fever with abdominal pain, or acute liver failure requires immediate local hospital care.
Stable patients should confirm whether original imaging and pathology can be reviewed. Remote medical-record review requires physician authorization. Final surgery or transplant eligibility requires full in-person assessment and current institutional approval.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating hepatobiliary and transplant records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor Lu, remote review, surgery, transplantation, immunotherapy, or a particular treatment is subject to doctor and hospital approval. CMCS does not guarantee appointments, donor organs, transplant listing, treatment eligibility, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor titles, clinical roles, transplant policy, treatment availability, and appointment arrangements may change. This profile is based on the supplied verified research document and is for general information only. It does not replace assessment by a qualified hepatobiliary and transplant team.
0 Kommentare